: AstraZeneca hikes earnings forecast as surging cancer drug sales offset plunging revenue from COVID vaccines
AstraZeneca shares jumped 3% after the Anglo-Swedish drugmaker said it expects its full-year revenues will increase at a higher rate than previously forecast